

5.21.246

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	August 1, 2025
<b>Subject:</b>	Lynozytic	<b>Page:</b>	1 of 5

---

**Last Review Date:** March 6, 2026

---

## Lynozytic

### Description

#### Lynozytic (linvoseltamab-gcpt)

#### Background

Lynozytic (linvoseltamab-gcpt) is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, Lynozytic activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells (1).

#### Regulatory Status

FDA-approved indication: Lynozytic is a bispecific BCMA-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (1).

Lynozytic has a boxed warning regarding cytokine release syndrome (CRS) and neurotoxicity. Initiate treatment with Lynozytic step-up dosing schedule to reduce risk of CRS. Withhold dose until CRS resolves or permanently discontinue based on severity. Neurotoxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), and serious and life-threatening reactions, can occur. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold dose until neurologic toxicity resolves or permanently discontinue based on severity. Lynozytic is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the Lynozytic REMS (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	August 1, 2025
<b>Subject:</b>	Lynozytic	<b>Page:</b>	2 of 5

---

Lynozytic may cause hepatotoxicity, neutropenia, and infections. Monitor liver enzymes, bilirubin, and complete blood count (CBC) at baseline and during treatment as clinically indicated. Signs and symptoms of infection should be monitored and treated appropriately. Do not initiate treatment in patients with active infections (1).

Lynozytic can cause fetal harm when administered to a pregnant woman. Pregnant women should be advised of the potential risk to a fetus. Females of reproductive potential should be advised to use effective contraception during treatment with Lynozytic and for 3 months after the last dose (1).

The safety and effectiveness of Lynozytic in pediatric patients less than 18 years of age have not been established (1).

## Related Policies

Blenrep, Elrexfio, Talvey, Tecvayli

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Lynozytic may be considered **medically necessary** if the conditions indicated below are met.

Lynozytic may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

Relapsed or refractory multiple myeloma (MM)

**AND ALL** of the following:

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	August 1, 2025
<b>Subject:</b>	Lynozytic	<b>Page:</b>	3 of 5

---

- a. Patient has received at least 4 prior therapies, including **ALL** of the following:
  - i. Anti-CD38 monoclonal antibody
  - ii. Proteasome inhibitor
  - iii. Immunomodulatory agent
- b. Prescriber is certified with the Lynozytic REMS program
- c. Prescriber agrees to monitor for signs and symptoms of cytokine release syndrome (CRS) and neurologic toxicity
- d. Prescriber agrees to monitor liver enzymes, bilirubin, and complete blood cell counts (CBC) at baseline and during treatment as clinically indicated
- e. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lynozytic and for 3 months after the last dose

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

Relapsed or refractory multiple myeloma (MM)

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber is certified with the Lynozytic REMS program
- c. Prescriber agrees to monitor for signs and symptoms of cytokine release syndrome (CRS) and neurologic toxicity
- d. Prescriber agrees to monitor liver enzymes, bilirubin, and complete blood cell counts (CBC) during treatment as clinically indicated
- e. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lynozytic and for 3 months after the last dose

### Policy Guidelines

## Pre - PA Allowance

None

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	August 1, 2025
<b>Subject:</b>	Lynozytic	<b>Page:</b>	4 of 5

---

## Prior - Approval Limits

**Duration** 12 months

## Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Lynozytic is indicated for the treatment of relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Lynozytic has a boxed warning for cytokine release syndrome and neurologic toxicity. Hepatotoxicity, neutropenia, and infections can occur in patients treated with Lynozytic; therefore liver enzymes, bilirubin, complete blood cell counts, and signs and symptoms of infections must be monitored. The safety and effectiveness of Lynozytic in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Lynozytic while maintaining optimal therapeutic outcomes.

### References

1. Lynozytic [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; July 2025.
2. NCCN Drugs & Biologics Compendium® Linvoseltamab-gcpt 2026. National Comprehensive Cancer Network, Inc. Accessed on January 15, 2026.

## Policy History

Date	Action
August 2025	Addition to PA
September 2025	Annual review and reference update
December 2025	Annual review and reference update
March 2026	Annual review and reference update

## Keywords

# 5.21.246

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	August 1, 2025
<b>Subject:</b>	Lynozytic	<b>Page:</b>	5 of 5

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.**